Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA‐REG OU...
Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA‐REG OUTCOME
About this item
Full title
Author / Creator
Publisher
England: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
England: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Aims
The EMPA‐REG OUTCOME trial demonstrated reductions in cardiovascular (CV) death and heart failure (HF) outcomes with empagliflozin, a sodium–glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes and established CV disease over a study period of 3 years. We aimed to investigate the early benefit–risk profile of empagliflozin i...
Alternative Titles
Full title
Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA‐REG OUTCOME
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_b6fd846244c241c3a346f6cbbd89db9f
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_b6fd846244c241c3a346f6cbbd89db9f
Other Identifiers
ISSN
2055-5822
E-ISSN
2055-5822
DOI
10.1002/ehf2.12891
